The case for cell-penetrating peptides

Sounds intriguing!

"A potentially transformative, yet unproven drug modality is gaining traction: helical cell-penetrating peptides. These strings of amino acids can elegantly gain entry to cells and access targets that other protein-based therapeutics, such as antibodies, can’t reach. Incoming chief executive of FogPharma, Mathai Mammen, discusses the next frontier of these drugs with Nature Reviews Drug Discovery as the company advances a first candidate into the clinic to take on a notorious driver of tumour progression, β-catenin."

The case for cell-penetrating peptides (behind paywall) Incoming FogPharma CEO Mathai Mammen discusses the next frontier of cell-penetrating peptides, as the company advances a first candidate into the clinic to take on β-catenin.

FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors FogPharma, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced the first patient has been dosed in a first-in-human Phase 1/2 clinical trial of, FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor. FOG-001 represents the first development candidate arising from FogPharma’s pioneering Helicon therapeutics, a new class of drugs capable of modulating protein-protein interactions that may otherwise be challenging to drug.